NCT04440007View on ClinicalTrials.gov

Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 9, 2020

Primary Completion Date

July 1, 2021

Study Completion Date

August 23, 2021

Conditions

Covid-19

Interventions

DRUG

Abivertinib

Abivertinib maleate is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor. The starting dose is 200 mg p.o. QD for up to 28 days.

OTHER

Standard of Care

Standard of Care as determined by the Investigator

Trial Locations (6)

20010

MedStar Washington Hospital Center, Washington D.C.

33511

Teradan Clinical Trials, Brandon

68114

Quality Clinical Research, Omaha

70601

Clinical Trials of SWLA, Lake Charles

71301

Alexandria Cardiology Clinic, Alexandria

77024

Memorial Hermann Memorial City Hospital, Houston

All Listed Sponsors

lead

Sorrento Therapeutics, Inc.

INDUSTRY

NCT04440007 - Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19 | Biotech Hunter | Biotech Hunter